See more : Inovalon Holdings, Inc. (INOV) Income Statement Analysis – Financial Results
Complete financial analysis of RAMM Pharma Corp. (RAMM.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RAMM Pharma Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- METASURFACE TECHNOLOGIES HOLDINGS L (8637.HK) Income Statement Analysis – Financial Results
- Notable Labs, Ltd. (NTBL) Income Statement Analysis – Financial Results
- Jupiter Wellness, Inc. (JUPW) Income Statement Analysis – Financial Results
- Japan Real Estate Investment Corporation (8952.T) Income Statement Analysis – Financial Results
- Fuyao Glass Industry Group Co., Ltd. (3606.HK) Income Statement Analysis – Financial Results
RAMM Pharma Corp. (RAMM.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rammpharma.com
About RAMM Pharma Corp.
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.07M | 3.90M | 4.12M | 5.44M | 5.61M | 8.35M |
| Cost of Revenue | 4.68M | 3.37M | 4.12M | 4.16M | 4.83M | 6.12M |
| Gross Profit | 381.82K | 530.51K | -7.64K | 1.28M | 783.19K | 2.22M |
| Gross Profit Ratio | 7.54% | 13.61% | -0.19% | 23.57% | 13.96% | 26.66% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.83M | 6.78M | 5.60M | 8.22M | 2.70M | 1.89M |
| Selling & Marketing | 230.69K | 451.63K | 90.80K | 82.39K | 81.13K | 133.15K |
| SG&A | 6.06M | 7.23M | 5.69M | 8.30M | 2.70M | 1.89M |
| Other Expenses | 0.00 | 1.22M | 940.62K | 556.97K | 143.60K | 0.00 |
| Operating Expenses | 7.47M | 8.46M | 6.63M | 8.86M | 2.70M | 1.89M |
| Cost & Expenses | 12.15M | 11.82M | 10.76M | 13.02M | 7.53M | 8.01M |
| Interest Income | 195.54K | 162.89K | 266.21K | 333.58K | 460.40K | 0.00 |
| Interest Expense | 72.08K | 13.30K | 12.83K | 57.76K | 453.71K | 416.06K |
| Depreciation & Amortization | 1.34M | 1.02M | 732.63K | 461.26K | 34.60K | 10.23K |
| EBITDA | -6.30M | -19.91M | -6.36M | -6.91M | -6.28M | -252.64K |
| EBITDA Ratio | -124.42% | -168.99% | -153.75% | -124.54% | -36.67% | 4.11% |
| Operating Income | -7.09M | -7.93M | -7.19M | -7.58M | -1.92M | 332.74K |
| Operating Income Ratio | -139.90% | -203.39% | -174.76% | -139.14% | -34.25% | 3.99% |
| Total Other Income/Expenses | -625.08K | -13.02M | 92.01K | 150.13K | -4.89M | -1.01M |
| Income Before Tax | -7.71M | -20.95M | -7.10M | -7.43M | -6.81M | -678.93K |
| Income Before Tax Ratio | -152.24% | -537.58% | -172.53% | -136.38% | -121.47% | -8.14% |
| Income Tax Expense | 9.69K | 8.39K | 5.56K | 4.94K | 5.50K | 5.65K |
| Net Income | -7.72M | -20.96M | -7.11M | -7.43M | -6.82M | -684.58K |
| Net Income Ratio | -152.43% | -537.79% | -172.66% | -136.47% | -121.56% | -8.20% |
| EPS | -0.06 | -0.17 | -0.07 | -0.07 | -0.14 | -0.01 |
| EPS Diluted | -0.06 | -0.17 | -0.07 | -0.07 | -0.14 | -0.01 |
| Weighted Avg Shares Out | 121.04M | 122.77M | 108.46M | 100.56M | 50.42M | 100.72M |
| Weighted Avg Shares Out (Dil) | 121.04M | 122.77M | 108.46M | 100.56M | 50.42M | 100.72M |
Source: https://incomestatements.info
Category: Stock Reports